Search

Your search keyword '"Burger, Judith A."' showing total 260 results

Search Constraints

Start Over You searched for: Author "Burger, Judith A." Remove constraint Author: "Burger, Judith A."
260 results on '"Burger, Judith A."'

Search Results

2. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits

3. Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

4. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

5. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

6. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies

7. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

8. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions

9. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

10. Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection

11. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

12. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike

14. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

15. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

16. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

17. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection

18. Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses

20. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

22. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

24. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

25. Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection

26. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

27. Fourth mRNA COVID-19 Vaccination in Immunocompromised Patients with Hematologic Malignancies

28. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

29. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

30. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer

31. Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

32. Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

33. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

34. Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual

35. HIV-1 neutralizing antibodies induced by native-like envelope trimers

36. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies

37. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron

38. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity

39. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients

40. Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability

41. CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer

42. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization

43. Mapping the antigenic diversification of SARS-CoV-2

44. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

45. Recent Infection With HCoV-OC43 Is Associated With Protection Against Sars-Cov-2 Infection

46. HIV-1 Germline-Targeting Vaccine Regimen Selects for Rare Immunoglobulin Insertions and Deletions Typical of VRC01-Class Antibodies

47. Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Patients With Inborn Errors of Immunity

50. A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

Catalog

Books, media, physical & digital resources